The trial will recruit patients who do not require invasive mechanical ventilation at the time of entering the study. Credit: Tumisu from Pixabay.

Eli Lilly has started patient enrolment for a Phase III clinical trial of baricitinib to treat adults hospitalised due to Covid-19 infection.

Oral JAK1/JAK2 inhibitor, baricitinib, is indicated in 70 countries to treat adults with moderately to severely active rheumatoid arthritis (RA). Lilly licensed the drug from Incyte.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Inhibition of JAK1 and JAK2 is expected to mitigate the cytokine storm related to the complications of Covid-19. The drug may block the host cell proteins involved in viral reproduction, decreasing the infected cells’ ability to produce more virus.

The Phase III trial will enrol approximately 400 patients across the US, Europe and Latin America. It will recruit patients who do not require invasive mechanical ventilation at the time of entering the study.

Trial participants will be given 4mg baricitinib daily or placebo for up to 14 days or until discharge from the hospital.

The primary endpoint of the trial is the proportion of patients who die or need non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by day 28.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Key secondary outcomes include clinical improvement at different time points, time to recovery, duration of hospitalisation, ventilator-free days, and mortality over a 28-day period.

Eli Lilly senior vice-president Patrik Jonsson said: “Lilly is committed to fighting this global pandemic, and this includes testing whether existing medicines including baricitinib could help treat the complications of Covid-19 in patients.

“This randomised controlled study is an important step in our understanding of baricitinib as a potential Covid-19 treatment.”

The data from this Phase III trial is expected to support results from the study of the drug plus remdesivir in the second phase of the ACTT-2 study conducted by the National Institute of Allergy and Infectious Diseases (NIAID).

Earlier this month, Lilly started dosing participants in the Phase I trial of antibody therapy LY-CoV555 to treat Covid-19. This is said to be the world’s first study to assess an antibody treatment for the disease.